Research
Diagnostics company to accelerate search for sporadic ALS therapies September 12, 2024 – FOR IMMEDIATE RELEASE LOS ANGELES – The ALS Network, formerly ALS Golden West, has awarded a $100,000…
In recognition of July as Disability Pride Month, the NIH Chief Officer for Scientific Workforce Diversity, Dr. Marie Bernard, discussed the importance of disability inclusion with Dr. Alison Cernich, Deputy…
The U.S. Food and Drug Administration has announced the establishment of a Rare Disease Innovation Hub. The Hub will connect and engage the rare disease community; help the community navigate…
MINNEAPOLIS – Moderate levels of physical activity and fitness may be linked to a reduced risk of amyotrophic lateral sclerosis (ALS) later in life, according to a new study published…
The May 2024 issue of Studio City Life Magazine featured ALS Network president and CEO Sheri Strahl, along with ALS Network Advisory Trustee Dr. Richard Smith. Readers received details on…
On April 9, Jaime Lafita, a native of Bilbao, Spain, who has been living with amyotrophic lateral sclerosis (ALS) since 2016, started his journey of the Death Valley Ride to…
Eva Feldman, M.D., Ph.D., FAAN, has been named the 2024 recipient of the Sheila Essey Award for ALS Research. Dr. Feldman has dedicated her career to studying neurodegenerative diseases and…
A trailblazer in the field of ALS research and therapy development, Richard Smith, MD, director of the Center for Neurologic Study, and a member of the ALS Network’s scientific review…
In January 2024, Jill Ann Goslinga, MD, MPH, Assistant Professor, UCSF Department of Neurology, gave a special presentation about the mechanisms of ALS medications at the ALS Network’s (formerly the…
Planned Phase 3b trial Designed to Confirm Efficacy and Safety of NurOwn in mild-to-moderate ALS patients NEW YORK, Feb. 27, 2024 /PRNewswire/ — BrainStorm Cell Therapeutics Inc. (NASDAQ: BCLI), a leading developer…